Role of the Effect of Inhibition of Neutral Endopeptidase on Vascular and Neural Complications in Streptozotocin-induced Diabetic Rats

Overview

Journal Eur J Pharmacol

Specialty Pharmacology

Date 2010 Nov 3

PMID 21040718

Citations 14

Authors

Christine L Oltman

Eric P Davidson

Lawrence J Coppey

Travis L Kleinschmidt

Brian Dake

Mark A Yorek

Affiliations

Soon will be listed here.

Abstract

We have previously shown that treating streptozotocin-induced diabetic rats, an animal model of type 1 diabetes, with Ilepatril (an inhibitor of neutral endopeptidase and angiotensin converting enzyme (ACE)) improves vascular and neural function. In this study we sought to determine the individual effect of inhibition of neutral endopeptidase and ACE on diabetes-induced vascular and neural dysfunction. After 4 weeks of untreated diabetes, rats were treated for 12 weeks with Ilepatril, Enalapril (ACE inhibitor) or Candoxatril (neutral endopeptidase inhibitor) followed by analysis of neural and vascular function. Diabetes caused slowing of motor and sensory nerve conduction, thermal hypoalgesia, reduction in intraepidermal nerve fiber density in the hindpaw and impairment in vascular relaxation to acetylcholine and calcitonin gene-related peptide in epineural arterioles of the sciatic nerve and to atrial natriuretic peptide and calcitonin gene-related peptide in renal arteries. Inhibition of neutral endopeptidase or ACE improved neural function; however, dual inhibition of neutral endopeptidase and ACE with Ilepatril tended to have the greatest efficacy. Ilepatril and Candoxatril treatment of diabetic rats was more efficacious in improving vascular responsiveness in epineurial arterioles than treatment with Enalapril. Ilepatril, Enalapril or Candoxatril treatment of diabetic rats were all efficacious in renal arteries. These studies suggest that combination therapy may be the most effective approach for treatment of diabetic neural and vascular complications.

Citing Articles

Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?.

Yorek M Curr Diabetes Rev. 2021; 18(5):e040521193121.

PMID: 33949936 PMC: 8965779. DOI: 10.2174/1573399817666210504101609.

Diabetic neuropathy in children and youth: New and emerging risk factors.

Akinci G, Savelieff M, Gallagher G, Callaghan B, Feldman E Pediatr Diabetes. 2020; 22(2):132-147.

PMID: 33205601 PMC: 11533219. DOI: 10.1111/pedi.13153.

Effect of Inhibition or Deletion of Neutral Endopeptidase on Neuropathic Endpoints in High Fat Fed/Low Dose Streptozotocin-Treated Mice.

Yorek M, Obrosov A, Lu B, Gerard C, Kardon R, Yorek M J Neuropathol Exp Neurol. 2016; 75(11):1072-1080.

PMID: 27634964 PMC: 7714044. DOI: 10.1093/jnen/nlw083.

Vascular Impairment of Epineurial Arterioles of the Sciatic Nerve: Implications for Diabetic Peripheral Neuropathy.

Yorek M Rev Diabet Stud. 2015; 12(1-2):13-28.

PMID: 26676659 PMC: 5397981. DOI: 10.1900/RDS.2015.12.13.

Rat Models of Diet-Induced Obesity and High Fat/Low Dose Streptozotocin Type 2 Diabetes: Effect of Reversal of High Fat Diet Compared to Treatment with Enalapril or Menhaden Oil on Glucose Utilization and Neuropathic Endpoints.

Holmes A, Coppey L, Davidson E, Yorek M J Diabetes Res. 2015; 2015:307285.

PMID: 26229968 PMC: 4503545. DOI: 10.1155/2015/307285.

References

Quaschning T, Duscio L, Shaw S, Grone H, Ruschitzka F, Luscher T . Vasopeptidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension. J Am Soc Nephrol. 2001; 12(11):2280-2287. DOI: 10.1681/ASN.V12112280. View

Arbin V, Claperon N, Fournie-Zaluski M, Roques B, Peyroux J . Effects of combined neutral endopeptidase 24-11 and angiotensin-converting enzyme inhibition on femoral vascular conductance in streptozotocin-induced diabetic rats. Br J Pharmacol. 2000; 130(6):1297-304. PMC: 1572201. DOI: 10.1038/sj.bjp.0703442. View

Finegold D, Lattimer S, NOLLE S, Bernstein M, Greene D . Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy. Diabetes. 1983; 32(11):988-92. DOI: 10.2337/diab.32.11.988. View

Schafer S, Linz W, Vollert H, Biemer-Daub G, Rutten H, Bleich M . The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy. Diabetologia. 2003; 47(1):98-103. DOI: 10.1007/s00125-003-1264-8. View

Weber M . Emerging treatments for hypertension: potential role for vasopeptidase inhibition. Am J Hypertens. 1999; 12(11 Pt 2):139S-147S. DOI: 10.1016/s0895-7061(99)00205-8. View

Yorek M . The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy. Curr Drug Targets. 2008; 9(1):77-84. DOI: 10.2174/138945008783431736. View

Taal M, Nenov V, Wong W, Satyal S, Sakharova O, Choi J . Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol. 2001; 12(10):2051-2059. DOI: 10.1681/ASN.V12102051. View

Chauhan S, Hobbs A, Ahluwalia A . C-type natriuretic peptide: new candidate for endothelium-derived hyperpolarising factor. Int J Biochem Cell Biol. 2004; 36(10):1878-81. DOI: 10.1016/j.biocel.2003.09.009. View

Edwards R, Pullen M, Nambi P . Distribution of neutral endopeptidase activity along the rat and rabbit nephron. Pharmacology. 1999; 59(1):45-50. DOI: 10.1159/000028304. View

10.

Vatter H, Schilling L, Schmiedek P, Ehrenreich H . Evidence for functional endothelin-converting enzyme activity in isolated rat basilar artery: effect of inhibitors. J Cardiovasc Pharmacol. 1998; 31 Suppl 1:S64-7. DOI: 10.1097/00005344-199800001-00021. View

11.

French J, Anderson B, Downs T, Dage R . Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J Cardiovasc Pharmacol. 1995; 26(1):107-13. DOI: 10.1097/00005344-199507000-00017. View

12.

Terata K, Coppey L, Davidson E, Dunlap J, Gutterman D, Yorek M . Acetylcholine-induced arteriolar dilation is reduced in streptozotocin-induced diabetic rats with motor nerve dysfunction. Br J Pharmacol. 1999; 128(3):837-43. PMC: 1571695. DOI: 10.1038/sj.bjp.0702856. View

13.

Pu Q, Schiffrin E . Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats. Am J Hypertens. 2001; 14(10):1067-72. DOI: 10.1016/s0895-7061(01)02157-4. View

14.

Coppey L, Gellett J, Davidson E, Dunlap J, Lund D, Salvemini D . Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br J Pharmacol. 2001; 134(1):21-9. PMC: 1572916. DOI: 10.1038/sj.bjp.0704216. View

15.

Oltman C, Davidson E, Coppey L, Kleinschmidt T, Lund D, Yorek M . Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Obesity (Silver Spring). 2008; 16(1):82-9. DOI: 10.1038/oby.2007.19. View

16.

Davidson E, Kleinschmidt T, Oltman C, Lund D, Yorek M . Treatment of streptozotocin-induced diabetic rats with AVE7688, a vasopeptidase inhibitor: effect on vascular and neural disease. Diabetes. 2007; 56(2):355-62. DOI: 10.2337/db06-1180. View

17.

Coppey L, Gellett J, Davidson E, Dunlap J, Yorek M . Effect of treating streptozotocin-induced diabetic rats with sorbinil, myo-inositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Int J Exp Diabetes Res. 2002; 3(1):21-36. PMC: 2478566. DOI: 10.1080/15604280212525. View

18.

Davidson E, Coppey L, Kleinschmidt T, Oltman C, Yorek M . Vascular and neural dysfunctions in obese Zucker rats: effect of AVE7688. Exp Diabetes Res. 2009; 2009:912327. PMC: 2695958. DOI: 10.1155/2009/912327. View

19.

Muangman P, Spenny M, Tamura R, Gibran N . Fatty acids and glucose increase neutral endopeptidase activity in human microvascular endothelial cells. Shock. 2003; 19(6):508-12. DOI: 10.1097/01.shk.0000055815.40894.16. View

20.

Gonzalez W, Soleilhac J, Fournie-Zaluski M, Roques B, Michel J . Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels. Eur J Pharmacol. 1998; 345(3):323-31. DOI: 10.1016/s0014-2999(98)00038-7. View